Listing 1 - 2 of 2 |
Sort by
|
Choose an application
Immunohistochemistry (IHC) is an ancillary method, widely used in pathologists’ practice, that allows identifying diagnostic and prognostic/predictive of therapeutic response protein markers on tissue samples by the use of specific monoclonal antibodies and chromogenic substances that guarantee the visualization of an antibody–antigene binding complex under a light microscope [1]. Coon et al., in 1941 [2], first introduced the use of fluorochrome-conjugated antibodies in clinical practice. Since then, IHC has gone from being a useful tool for identifying the differentiation line of otherwise undifferentiated cells to a technique capable of providing not only diagnostic but also prognostic and predictive indications of responses to specific therapeutic options [1,3]. The abovementioned peculiarities have made IHC one of the most used ancillary methods in the histopathological approach to human neoplastic and non-neoplastic diseases [3-5]. This Special Issue contains 11 accepted papers that provide readers with a comprehensive update on current and future applications of IHC in medical practice.
training exercise --- NGAL --- VDR --- kidney --- heart --- immunohistochemistry --- ABCB5 --- uveal melanoma --- prognosis --- metastasis --- pericardium --- cytokeratin --- c-kit --- PDGFR --- initial lymphatics --- macroH2A --- prognostic factor --- SLC22A12 --- URAT1 --- hypouricemia --- uric acid transporters --- excretion fraction of uric acid --- Hsp27 --- Hsp60 --- Hsp70 --- Hsp90 --- molecular chaperone --- chaperonopathies --- thyroid --- follicular adenoma --- follicular carcinoma --- differential diagnosis --- carcinogenesis --- matrix metalloproteinases --- temporomandibular joint disorder --- temporomandibular joint --- DEN --- liver --- inflammation --- ultra-structural changes --- oxidative stress --- EGCG --- Vitamin D --- prostate cancer --- urinary tract malformations --- megacystis --- enteric nervous system --- outcome and prognosis --- WT1 --- human embryonal/fetal tissues --- neoplastic tissue --- n/a
Choose an application
Immunohistochemistry (IHC) is an ancillary method, widely used in pathologists’ practice, that allows identifying diagnostic and prognostic/predictive of therapeutic response protein markers on tissue samples by the use of specific monoclonal antibodies and chromogenic substances that guarantee the visualization of an antibody–antigene binding complex under a light microscope [1]. Coon et al., in 1941 [2], first introduced the use of fluorochrome-conjugated antibodies in clinical practice. Since then, IHC has gone from being a useful tool for identifying the differentiation line of otherwise undifferentiated cells to a technique capable of providing not only diagnostic but also prognostic and predictive indications of responses to specific therapeutic options [1,3]. The abovementioned peculiarities have made IHC one of the most used ancillary methods in the histopathological approach to human neoplastic and non-neoplastic diseases [3-5]. This Special Issue contains 11 accepted papers that provide readers with a comprehensive update on current and future applications of IHC in medical practice.
Medicine --- training exercise --- NGAL --- VDR --- kidney --- heart --- immunohistochemistry --- ABCB5 --- uveal melanoma --- prognosis --- metastasis --- pericardium --- cytokeratin --- c-kit --- PDGFR --- initial lymphatics --- macroH2A --- prognostic factor --- SLC22A12 --- URAT1 --- hypouricemia --- uric acid transporters --- excretion fraction of uric acid --- Hsp27 --- Hsp60 --- Hsp70 --- Hsp90 --- molecular chaperone --- chaperonopathies --- thyroid --- follicular adenoma --- follicular carcinoma --- differential diagnosis --- carcinogenesis --- matrix metalloproteinases --- temporomandibular joint disorder --- temporomandibular joint --- DEN --- liver --- inflammation --- ultra-structural changes --- oxidative stress --- EGCG --- Vitamin D --- prostate cancer --- urinary tract malformations --- megacystis --- enteric nervous system --- outcome and prognosis --- WT1 --- human embryonal/fetal tissues --- neoplastic tissue --- training exercise --- NGAL --- VDR --- kidney --- heart --- immunohistochemistry --- ABCB5 --- uveal melanoma --- prognosis --- metastasis --- pericardium --- cytokeratin --- c-kit --- PDGFR --- initial lymphatics --- macroH2A --- prognostic factor --- SLC22A12 --- URAT1 --- hypouricemia --- uric acid transporters --- excretion fraction of uric acid --- Hsp27 --- Hsp60 --- Hsp70 --- Hsp90 --- molecular chaperone --- chaperonopathies --- thyroid --- follicular adenoma --- follicular carcinoma --- differential diagnosis --- carcinogenesis --- matrix metalloproteinases --- temporomandibular joint disorder --- temporomandibular joint --- DEN --- liver --- inflammation --- ultra-structural changes --- oxidative stress --- EGCG --- Vitamin D --- prostate cancer --- urinary tract malformations --- megacystis --- enteric nervous system --- outcome and prognosis --- WT1 --- human embryonal/fetal tissues --- neoplastic tissue
Listing 1 - 2 of 2 |
Sort by
|